ArticleFrontiers in molecular biosciences2026
Serum bile acid metabolic profiles in polycystic ovary syndrome: insights from targeted metabolomics and correlation with embryonic parameters.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder. In this study, we characterize serum bile acids (BAs) metabolic profiles in PCOS patients using targeted metabolomics and investigated their correlation with embryonic parameters, thereby elucidating the role of BAs in the pathogenesis of PCOS. Methods: We enrolled 20 PCOS patients undergoing Results: We identified 43 BA metabolites, including 22 upregulated and 21 downregulated species. We selected 11 key BA metabolites, of which six demonstrated diagnostic potential based on ROC curve analysis. We found negative correlations between these metabolites and embryonic parameters, although none of the correlations were statistically significant. Conclusion: Although targeted metabolomics is an exploratory tool, it is valuable for identifying potential diagnostic biomarkers in PCOS, offering preliminary novel insights into the pathophysiology of PCOS. The findings of this study suggest that targeted modulation of the metabolism of BA may represent an emerging and promising strategy for ameliorating metabolic and reproductive dysfunction in PCOS; however, these findings need to be validated in larger, independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.